Humanitas University, Milan, Italy.
Interventional Cardiology Unit, GVM Care & Research Maria Cecilia Hospital, Via Madonna di Genova 1, Cotignola, RA, 48033, Italy.
Future Cardiol. 2022 Jul;18(7):523-537. doi: 10.2217/fca-2021-0064. Epub 2022 Jun 27.
Refractory angina represents the final stage of chronic coronary artery disease, where anginal symptoms persist despite complete epicardial coronary artery revascularization and maximally tolerated pharmacological therapy. Percutaneous narrowing of the coronary sinus with the coronary sinus reducer (Reducer, Neovasc, Inc., Richmond, Canada) device was first attempted in humans in 2005 and has been shown to improve angina symptoms and the quality of life of patients suffering chronic refractory angina. It was recently included in the European guidelines for the management of chronic coronary syndrome and is progressively gaining popularity. The authors hereby provide a review of current literature on the topic, intending to facilitate insights and to promote further research on this device and its clinical applications.
难治性心绞痛代表慢性冠状动脉疾病的终末阶段，即使进行了完全的心脏外膜冠状动脉血运重建和最大耐受药物治疗，心绞痛症状仍持续存在。2005 年首次尝试使用冠状动脉窦缩窄器（Coronary Sinus Reducer，Neovasc，Inc.，加拿大里士满）对人体进行经皮冠状动脉窦缩窄，结果表明该方法可改善慢性难治性心绞痛患者的心绞痛症状和生活质量。该方法最近被纳入欧洲慢性冠状动脉综合征管理指南，并逐渐普及。作者在此对该主题的现有文献进行综述，旨在为该设备及其临床应用的研究提供思路和促进。
